Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;14(4):456-66.
doi: 10.1016/j.cbpa.2010.04.008. Epub 2010 May 7.

The chemical biology of new drugs in the development for tuberculosis

Affiliations
Review

The chemical biology of new drugs in the development for tuberculosis

Clifton E Barry 3rd et al. Curr Opin Chem Biol. 2010 Aug.

Abstract

With the worldwide emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (Mtb), there are serious concerns about the continued ability to contain this disease. We discuss the most promising new drugs in late-stage development that might be useful in treating MDR and XDR forms of the disease. These agents have novel mechanisms of action that are not targeted by the standard drugs used presently to treat susceptible strains.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Homology model of the Mtb c subunit of ATP synthase. Position 28 (left, spheres) is the aspartate residue equivalent to D32 in M. smegmatis. Position 63 (right sphere) is the Ala residue mutated to a Pro in the Mtb strain reisitant to TMC207. This figure was generously provided by Josh Goldman and Mark Girvin, Department of Biochemistry, Albert Einstein College of Medicine.
Figure 3
Figure 3
Figure 4
Figure 4
Figure 5
Figure 5
Figure 6
Figure 6

Similar articles

Cited by

References

    1. Tsukamura M. A comparison of the time of in vivo resistance development of tubercle bacilli to rifampicin, kanamycin, ethionamide, lividomycin, and enviomycin (tuberactinomycin-N) in patients with chronic cavitary tuberculosis (author’s transl) Kekkaku. 1978;53:495–498. - PubMed
    1. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med. 2005;171:699–706. - PubMed
    1. Fox W, Mitchison DA. Short-course chemotherapy for tuberculosis. Lancet. 1976;2:1349–1350. An authoritative history and discussion of the development of the multi-drug chemotherapy currently used in the treatment of Tuberculosis. - PubMed
    1. Neff M. ATS, CDC, and IDSA update recommendations on the treatment of tuberculosis. Am Fam Physician. 2003;68:1854, 1857–1858, 1861–1852. - PubMed
    1. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7:6–21. - PubMed

MeSH terms

LinkOut - more resources